Clinical trial waiver in China opens door to 2022 filing for ALK's dust mite allergy tablet

3 March 2022
alk-abello-big-1

Danish allergy immunotherapy specialist ALK Abello (ALKB: DC) said today that it expects to submit a registration application in China for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet already in 2022, sending its shares up 3% by close of trading.

In preparation for this application, ALK has completed a Phase I trial in China and had initiated a Phase III, local registration trial in adult allergic rhinitis. However, the Phase III trial has been paused since 2020 as a consequence of the COVID pandemic.

A registration trial waiver from the Chinese authorities now allows ALK to submit a Biologics Licence Application (BLA) in China without finalizing the local Phase III trial. Instead, the waiver permits the relevant data in Chinese patients to be obtained as a follow-up activity, after the tablet’s potential approval and launch.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology